Skip to content
Catalyst brief · Phase 2/3 readout · 26 days

ReMEDy2: Recombinant human tissue kallikrein in Acute Stroke

DiaMedica Therapeutics Inc · $DMAC · built 19 Nov 2026 from 16 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The ReMEDy2 trial has a robust design with a double-blind and randomised allocation, which can provide convincing results for its main goal of Stroke Recovery measured over 90 days. F3 F4 F5 F6
  • The trial plans to enrol 728 patients, which is an increase from the initial target of 364, and has two study arms, which can help to establish the efficacy of the treatment. F2 F7

Base rates

  • Historically, 62.1% of Phase 3 programmes in cardiovascular and metabolic moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F12
  • The company has had 1 past trial-result day with an average absolute share move of 35.0%, which is a past result and not a prediction of future performance. F13
  • The historical success rate and past result-day moves are averages and not forecasts, and should not be taken as a prediction of the outcome of this trial. F12 F13

Filings

  • The company has $35M in cash and short-term investments, which is expected to last about 12 months, providing a cash runway beyond the trial's primary completion date. F14 F15
  • There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F16
  • The primary completion date of the trial is estimated to be Dec 2026, which is 26 days from the current date. F9
  • Historically, 62.1% of Phase 3 programmes in the same group have moved on to a regulatory filing, although this is an industry average and not specific to this trial. F12

The case for

  • The ReMEDy2 trial has a robust design with a double-blind and randomised allocation, which can provide convincing results for its main goal of Stroke Recovery measured over 90 days. F3 F4 F5 F6
  • The trial's design, including two study arms and a plan to enrol 728 patients, can help to establish the efficacy of the treatment. F2 F7

The case against

  • The trial's large patient enrollment target and multiple study sites may pose logistical challenges, potentially leading to delays or difficulties in meeting the primary completion date. F2 F8
  • Despite the DataCutoff timing model's estimate, the actual trial completion date may be later than expected, given the complexity of the trial design and the number of patients involved. F11 F9

Open questions

  • Will the ReMEDy2 trial meet its primary completion date of Dec 2026?
  • Can the double-blind and randomised design of the trial provide convincing results for Stroke Recovery?
  • Will the trial's outcome lead to a regulatory filing, given the historical 62.1% success rate of Phase 3 programmes in cardiovascular and metabolic?

5 AI sentences were removed by the fact check.

The facts

The trial

  • F1ReMEDy2 is a Phase 2/3 trial of Recombinant human tissue kallikrein in Acute Stroke, sponsored by DiaMedica Therapeutics Inc (DMAC). source ↗
  • F2The trial plans to enrol 728 patients; the target first registered was 364. source ↗

What counts as success

When

  • F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10That date is 39.0 months later than the date first registered for this trial (Sep 2023). source ↗
  • F11The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

  • F8The registry lists 86 sites, of which 5 have closed. source ↗

Base rates

  • F12Historically 62.1% of Phase 3 programmes in cardiovascular and metabolic (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F13DMAC has had 1 past trial-result days on record, with an average absolute share move of 35.0%. source ↗

Money, insiders and FDA

  • F14DMAC reported $35M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F15At the last 12 months' rate of spending (about $3M a month) that cash lasts about 12 months, to around Oct 2027, which is after the registry's primary completion date. source ↗
  • F16No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.